Mimedx Group earnings were $6.2M for the trailing 12 months ending Jun 30, 2026, with -81.8% growth year over year. The latest MDXG earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$14.8M, up 36.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MDXG reported annual earnings of $48.6M, with 14.5% growth.
MDXG past earnings growth
How has MDXG's earnings growth performed historically?
On MDXG's earnings call on Jul 29, 2026, Mimedx Group (NASDAQ: MDXG) reported Q2 2026 earnings per share (EPS) of -$0.10, up 242.86% year over year. Total MDXG earnings for the quarter were -$14.84 million. In the same quarter last year, Mimedx Group's earnings per share (EPS) was $0.07.
As of the last Mimedx Group earnings report, Mimedx Group is currently profitable. Mimedx Group's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $6.24 million, a 80.61% decrease year over year.
What was MDXG's earnings growth in the past year?
As of Mimedx Group's earnings date in Jul 29, 2026, Mimedx Group's earnings has grown -81.82% year over year. This is 100.8 percentage points lower than the US Biotechnology industry earnings growth rate of 18.98%. MDXG earnings in the past year totalled $6.24 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.